Zargis Receives FDA Clearance for Signal X6 Telemedicine Device; OK Allows Delivery to US Army
September 17 2009 - 9:10AM
PR Newswire (US)
STAMFORD, Conn., Sept. 17 /PRNewswire-FirstCall/ -- Zargis Medical
Corp., a spin-off from Siemens Corporate Research (NYSE:SI) and a
majority-owned subsidiary of Speedus Corp. (NASDAQ:SPDE), announced
today it has received U.S. Food and Drug Administration (FDA)
clearance to market its new Signal X6(TM) device. Zargis also
announced the delivery of seven Signal X6 devices to the U.S. Army
for deployment in six Department of Defense medical facilities.
Signal X6 is noninvasive, easy to use and simultaneously records
heart and lung sounds from six adhesive sensors. The recordings can
be evaluated locally or, for locations where a cardiac specialist
is not immediately available for consultation, transmitted through
the Internet for remote evaluation. Signal X6 and our recently
launched Zargis Cardioscan(TM) device were both designed for
user-friendly digital heart sound analysis. The configuration of
the Signal X6 provides a unique telemedicine resource in situations
where evaluations would benefit from high fidelity multi-channel
synchronous recordings. "As healthcare systems continue to demand
improved outcomes with utilization of fewer resources, we believe
that Signal X6 will provide cost-effective, high quality cardiac
analysis in situations where it's not practical for a patient to
visit a specialist," said John Kallassy, Zargis' CEO. Prototypes
for Signal X6 were first developed with funding from the
Telemedicine and Advanced Technology Research Center (TATRC)
through the AAMTI program. The AAMTI program provides funding to
AMEDD personnel to demonstrate technology and document the impact
on cost, access and quality of care. TATRC (http://www.tatrc.org/)
is an element of the United States Army Medical Research and
Materiel Command (USAMRMC). About Zargis Medical Corp. Zargis
Medical Corp. develops advanced diagnostic decision support
products and services for primary care physicians, pediatricians,
cardiologists and other healthcare professionals. Zargis was formed
in 2001 when Siemens Corporate Research, a division of Siemens AG
(NYSE:SI), and Speedus Corp. co-invested to develop and market an
advanced acoustic technology designed to detect heart abnormalities
identified through analysis of heart sounds. For additional
information about Zargis or Speedus Corp., contact Peter Hodge at
888.773.3669 (ext. 23) or or visit the following Web sites:
http://www.zargis.com/ and http://www.speedus.com/. Statements
contained herein that are not historical facts, including but not
limited to statements about the Company's product, corporate
identity and focus, may be forward-looking statements that are
subject to a variety of risks and uncertainties. There are a number
of important factors that could cause actual results to differ
materially from those expressed in any forward-looking statements
made by the Company, including, but not limited to, the continuing
development of the Company's sales, marketing and support efforts.
DATASOURCE: Speedus Corporation CONTACT: Peter Hodge, +888-773-3669
(ext. 23), Web Site: http://www.speedus.com/
Copyright
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Oct 2023 to Oct 2024